Skip to main content
. 2023 May 3;8:177. doi: 10.1038/s41392-023-01427-2

Fig. 5.

Fig. 5

GPCRs-targeting drugs for neurodegenerative diseases and psychiatric disorders. a Numbers of compounds approved for clinical use or under clinical trials. b Summary of the action modes of GPCR-targeted agents for treatment of neuropsychiatric diseases